Advertisement

Picture EBD Group BIO-Europe Spring 2017 BES Barcelona Spain March 600x60px
Document › Details

Bruker Corporation. (12/2/10). "Press Release: Public Hospital Network of Paris (Assistance Publique Hôpitaux de Paris) Has Selected Bruker’s IVD MALDI Biotyper for MALDI-TOF-based Microbial Identification". Paris.

Region Region Paris
  Country France
Organisations Organisation Bruker Daltonique S.A.
  Group Bruker Corporation (Group)
  Organisation 2 Assistance Publique-Hôpitaux de Paris (l’AP-HP / APHP)
Products Product MALDI Biotyper IVD-CE system
  Product 2 clinical diagnostics
Index term Index term APHP–Bruker Corp: mass spectrometer, 201012– supply MALDI Biotyper as excl MALDI-TOF solution 3 new orders + 2 already used for years
Persons Person Mogabure, Peio (Bruker 201012 Microbiology Business Developm Manager Bruker Daltonique SA)
  Person 2 Rottmann, Martin (Univ Versailles 201012 Associate Professor + Hospital Raymond Ponicaré, Garches)
     


At the 30th Reunion Interdisciplinaire de Chimothérapie Anti-Infectieuse (RICAI), Bruker announces that the Assistance Publique Hôpitaux de Paris (APHP) has selected Bruker's IVD MALDI Biotyper as their exclusive MALDI-TOF mass spectrometry-based microbial identification tool. APHP is the association of all 44 public hospitals in Paris, and is the largest public health network in France. The APHP is providing medical service for the complete metropolitan area of Paris with more than ten million inhabitants.

As an immediate result of this selection, the three Hospitals Bichat, Cochin and Lariboisière have each already ordered an IVD MALDI Biotyper system. Additionally, the Hospitals Necker and Pitié-Salpétrière had previously selected and have already been working with Bruker's MALDI-TOF mass spectrometers for several years. The APHP hospitals will use the IVD MALDI Biotyper for mass spectrometry-based identification of microorganisms, such as gram-negative bacteria, gram-positive bacteria and yeasts. Due to typically much faster time-to-result (TTR) and lower consumables cost, MALDI Biotyper-based microbial identification is currently more and more replacing classical biochemical identification approaches. In fact, MALDI Biotyper molecular identification is almost as specific as sequence-based 'gold standard' identification, and allows the rapid identification of most bacterial species within minutes.

Dr. Martin Rottman, Associate Professor of Microbiology at University of Versailles and Hospital Raymond Poincaré, Garches pointed out: "We want to use MALDI-TOF mass spectrometry identification in routine clinical microbiology applications to achieve the precision in bacterial identification that could otherwise only be obtained using time-consuming sequence based identification. Indeed the currently available biochemical methods fail to identify many micro-organisms involved in bone and joint infections. The setup of the ISMABIOs regional network for the surveillance and treatment of bone and joint infection, jointly funded by the Region Ile de France through the DIM Malinf program and AP-HP, the hospital of Versailles and the hospital Croix Saint Simon will use MALDI-TOF based bacterial identification to achieve rapid and exact microbial identification in this demanding task. Bruker's MALDI Biotyper was selected as an obvious choice because it is the only platform with CE-IVD marking and the only system currently validated for clinical use in Europe. Moreover, the instrument can be connected to the laboratory information system for defined IVD applications, as well as be used as an open, research oriented, development platform."

Mr. Peio Mogabure, Microbiology Business Development Manager at Bruker Daltonique S.A., added: "Our selection by the APHP hospital association is a major milestone for further establishing the IVD MALDI Biotyper as the standard mass spectrometry tool in routine laboratories for microbial identification in France. During the last two years, we have successfully implemented the technology at several university hospitals. With this selection, our market leading position for MALDI-TOF mass spectrometry based microbial identification is further underpinned."

About the Bruker MALDI Biotyper

Bruker's proprietary MALDI Biotyper solution enables molecular identification, taxonomical classification or dereplication of microorganisms like bacteria, yeasts and fungi. Classification and identification of microorganisms is achieved reliably and quickly using proteomic fingerprinting by high-throughput

MALDI-TOF mass spectrometry. Applications include clinical routine microbial identification, environmental and pharmaceutical analysis, taxonomical research, food and consumer product processing and quality control, as well as marine microbiology. Bruker's robust MALDI Biotyper method requires minimal sample preparation efforts and offers low consumables cost per sample. The MALDI Biotyper is available in a research-use-only version, as well as in an IVD-CE version according to EU directive EC/98/79 in certain European countries. For more information, please visit www.maldibiotyper.com.

ABOUT BRUKER

For more information about Bruker Daltonics and Bruker Corporation (NASDAQ: BRKR), please visit www.bdal.com and www.bruker.com.

CAUTIONARY STATEMENT OF BRUKER

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to adverse changes in conditions in the global economy and volatility in the capital markets, the integration of businesses we have acquired or may acquire in the future, changing technologies, product development and market acceptance of our products, the cost and pricing of our products, manufacturing, competition, dependence on collaborative partners and key suppliers, capital spending and government funding policies, changes in governmental regulations, intellectual property rights, litigation, and exposure to foreign currency fluctuations. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2009, our most recent quarterly reports on Form 10-Q and our current reports on Form 8-K. We disclaim any intent or obligation to update these forward-looking statements other than as required by law.

Bruker Daltonique S.A
Peio Mogabure, +33-3-88066027
Microbiology Business Development Manager
peio.mogabure@bruker.fr

   
Record changed: 2016-03-20

Advertisement

BCNP Consultants European Chemistry Partnering 2017 Ffm Germany 600x60px

More documents for Bruker Corporation (Group)


To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

BCNP Consultants European Chemistry Partnering 2017 Ffm Germany 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px BCNP Consultants European Chemistry Partnering 2017 Ffm Germany 120x180px Picture EBD Group BIO-Europe Spring 2017 BES Barcelona Spain March 120x180px Picture AB Sciex Berliner LCMSMS Symposium 2017 Right 120x80px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px